Peer-reviewed publications

View my Bibliography from NCBI

12. Use of Molecular Modeling to Design Selective-NTS2 Neurotensin Analogues.
Fanelli R, Floquet N, Besserer-Offroy É, Delort B, Vivancos M, Longpré JM, Renault P, Martinez J, Sarret P, Cavelier F.
J Med Chem. 2017 Apr 27;60(8):3303-3313. doi: 10.1021/acs.jmedchem.6b01848. Epub 2017 Apr 10.
 PMID: 28368584
[Pubmed] [Journal[Full-text article[Full-text on ResearchGate]
11. Signaling signature of neurotensin receptor type 1 with endogenous ligands.
Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, Leduc R.
Eur J Pharmacol. 2017 Jun 15;805:1-13. doi: 10.1016/j.ejphar.2017.03.046. Epub 2017 Mar 22.
 PMID: 28341345
[Pubmed] [Journal] [Full-text article]
10. Structure-activity relationship of novel macrocyclic biased apelin receptor agonists.
Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.
Org Biomol Chem. 2017 Jan 4;15(2):449-458. doi: 10.1039/c6ob02247b. Epub 2016 Dec 7.
 PMID: 27924341
[Pubmed] [Journal]
9. Design, Synthesis, and Biological Evaluation of Novel CXCR4 Inverse Agonists.
Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault E, Escher E.
Org Biomol Chem. 2016 Nov 2;14(43):10298-10311. Epub 2016 Oct 4.
 PMID: 27752700
[Pubmed] [Journal]
8. Structure Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.
Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault E, Escher E.
J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.
PMID: 27434274
[Pubmed] [Journal] [Full-text article]
7. Identification of 2-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic acid (NTRC-844) as a selective antagonist for the Rat Neurotensin receptor type 2.
Thomas JB, Vivancos M, Giddings AM, Wiethe RW, Warner KR, Murza A, Besserer-Offroy É, Longpre JM, Runyon SP, Decker AM, Gilmour BP, Sarret P.
ACS Chem Neurosci. 2016 Sep 21;7(9):1225-31. doi: 10.1021/acschemneuro.6b00097. Epub 2016 Jul 13.
PMID: 27359371
[Pubmed] [Journal] [Full-text article]
6. Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions.
Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpre JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault E.
J Med Chem. 2016 Apr 14;59(7):2962-72. doi: 10.1021/acs.jmedchem.5b01549. Epub 2016 Mar 30.
PMID: 26986036
[Pubmed] [Journal] [Full-text article] [Full-text on ResearchGate]
5. Stereoselective synthesis of β-(5-arylthiazolyl) α-amino acids and use in neurotensin analogues.
Hapău D, Rémond E, Fanelli R, Vivancos M, René A, Côté J, Besserer-Offroy É, Longpré JM, Martinez J, Zaharia V, Sarret P, Cavelier F.
Euro J Org Chem. 2016 Feb 12;2016(5):1017-1024. doi: 10.1002/ejoc.201501495 Epub 2016 Jan 18.
[Journal] [Full-text article] [Full-text on ResearchGate]
4. Synthesis, in vitro and in vivo characterization of (L)-(trimethylsilyl)alanine containing neurotensin analogues.
*Fanelli R, *Besserer-Offroy É, René A, Côté J, Tétrault P, Collerette-Tremblay J, Longpré JM, Leduc R, Martinez J, Sarret P, Cavelier F.
 J Med Chem. 2015 Oct 8;58(19):7785-95. doi: 10.1021/acs.jmedchem.5b00841. Epub 2015 Sep 16.
PMID: 26348111
[Pubmed] [Journal] [Full-text article] [Full-text on ResearchGate]
3. C-terminal modifications of apelin-13 significantly change ligand binding, receptor signaling and hypotensive action.
Murza A, Besserer-Offroy E, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, Marsault E.
J Med Chem. 2015 Mar 12;58(5):2431-40. doi: 10.1021/jm501916k. Epub 2015 Feb 24.
PMID: 25668242
[Pubmed] [Journal] [Full-text article]
2. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.
Demeule M, Beaudet N, Régina A, Besserer-Offroy É, Murza A, Tétreault P, Belleville K, Ché C, Larocque A, Thiot C, Béliveau R, Longpré JM, Marsault É, Leduc R, Lachowicz JE, Gonias SL, Castaigne JP, Sarret P.
J Clin Invest. 2014 Mar;124(3):1199-213. doi: 10.1172/JCI70647. Epub 2014 Feb 17.
PMID: 24531547
[Pubmed] [Journal] [Full-text article] [Full-text on ResearchGate]
1. Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability.
Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault É.
ChemMedChem. 2012 Feb 6;7(2):318-25. doi: 10.1002/cmdc.201100492. Epub 2011 Dec 13.
PMID: 22170700
[Pubmed] [Journal] [Full-text article] [Full-text on ResearchGate]

Conference proceedings

2. Synthetic Agonists for the CXCR4 Receptor: SAR, Signaling Pathways and Peptidomimetic Transition.
Mona C, Lefrançois M, Boulais PE, Besserer-Offroy É, Leduc R, Heveker N, Marsault É, Escher E.
23rd American Peptide Symposium (Peptides Across the Pacific), Waikoloa, Hawai’I, USA; 06/2013
[Proceedings book] [Full-text proceeding]
1. Elucidation of the structure-activity relationships of Apelin: Influence of unnatural amino acids on binding, signaling and plasma stability.
Murza A, Parent AJ, Besserer-Offroy É, Beaudet N, Sarret P, Marsault É.
32nd European Peptide Symposium, Athens, Greece; 09/2012
[Proceedings book] [Full-text proceeding]

Published conference abstracts

5. Agonist-Antagonist Transition in CXCR4 Ligands
Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.
J. Pharmacol. Toxicol. Methods. 2017 Nov. 13; 88(2):170-171. doi: 10.1016/j.vascn.2017.09.012
[Journal] [Full-text abstract]
4. C-terminal modifications of Apelin-13: generation of new biased analogs and impact on hypotensive effect.
Besserer-Offroy É, Murza A, Bérubé P, Dinh T, Longpré JM, Leduc R, Marsault É, Sarret P.
J Popul Ther Clin Pharmacol. 2014 Sep 17; 21(2):e318-e319.
[Journal] [Full-text abstract]
3. Design, synthesis and exploration of structure-function relationship studies of new macrocyclic derivatives of apelin-13.
Murza A, Besserer-Offroy É, Bérubé P, Longpré JM, Sarret P, Marsault É.
J Popul Ther Clin Pharmacol. 2014 Sep 17; 21(2):e330-e330.
[Journal] [Full-text abstract]
2. Deciphering the structure-function of Apelin with unnatural amino acids and macrocycles.
Marsault É, Murza A, Besserer-Offroy É, Bérubé P, Longpré JM, Sarret P.
Journal of Peptide Science. 2014 Sep; 20(S1):S54-S55. doi: 10.1002/psc.2687. Epub 2014 Aug 20.
[Journal] [Full-text abstract]
1. Use of peptide technology for analgesic brain delivery.
Besserer-Offroy É, Demeule M, Beaudet N, Regina A, Tetreault P, Belleville K, Che C, Larocque A, Lachowicz JE, Castaigne JP, Sarret P.
Biopolymers. 2013 May 1; 100(3):264-264. doi: 10.1002/bip.22277. Epub 2013 Jun 6.
[Journal] [Full-text abstract]